GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theralink Technologies Inc (OTCPK:THER) » Definitions » ROC (Joel Greenblatt) %

Theralink Technologies (Theralink Technologies) ROC (Joel Greenblatt) % : -3,758.06% (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Theralink Technologies ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Theralink Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -3,758.06%.

The historical rank and industry rank for Theralink Technologies's ROC (Joel Greenblatt) % or its related term are showing as below:

THER' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -161129.41   Med: -806.27   Max: 156345.45
Current: 372.94

During the past 13 years, Theralink Technologies's highest ROC (Joel Greenblatt) % was 156345.45%. The lowest was -161129.41%. And the median was -806.27%.

THER's ROC (Joel Greenblatt) % is ranked better than
98.35% of 1458 companies
in the Biotechnology industry
Industry Median: -321.77 vs THER: 372.94

Theralink Technologies's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Theralink Technologies ROC (Joel Greenblatt) % Historical Data

The historical data trend for Theralink Technologies's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralink Technologies ROC (Joel Greenblatt) % Chart

Theralink Technologies Annual Data
Trend Feb14 Feb15 Dec16 Dec17 Dec18 Dec19 Sep20 Sep21 Sep22 Sep23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -50,713.33 -553.13 -512.55 -807.42 -805.12

Theralink Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7,369.50 -808.58 2,342.42 3,857.98 -3,758.06

Competitive Comparison of Theralink Technologies's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Theralink Technologies's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theralink Technologies's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theralink Technologies's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Theralink Technologies's ROC (Joel Greenblatt) % falls into.



Theralink Technologies ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.024 + 0 + 0.241) - (4.453 + 0.145 + 16.606)
=-20.939

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.046 + 0 + 0.187) - (5.313 + 0.141 + 29.693)
=-34.914

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Theralink Technologies for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-57.968/( ( (1.572 + max(-20.939, 0)) + (1.513 + max(-34.914, 0)) )/ 2 )
=-57.968/( ( 1.572 + 1.513 )/ 2 )
=-57.968/1.5425
=-3,758.06 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theralink Technologies  (OTCPK:THER) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Theralink Technologies ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Theralink Technologies's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Theralink Technologies (Theralink Technologies) Business Description

Traded in Other Exchanges
N/A
Address
15000 West 6th Avenue, Suite 400, Golden, CO, USA, 80401
Theralink Technologies Inc is a proteomics-based, precision medicine and molecular profiling company that specializes in patented Reverse Phase Protein Array (RPPA) and protein biomarker assay services that target multiple areas of oncology. The company provides precision oncology data through its Theralink Reverse Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. The firm is currently generating revenue with its multiple biopharma contracts and by testing breast cancer patients with its patented Theralink assay.
Executives
Danica Holley director 7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814
Matthew Wilson Schwartz director 15000 W. 6TH AVENUE, SUITE 400, GOLDEN CO 80401
Chilcott, Iii Thomas E. officer: Chief Financial Officer 373 INVERNESS PARKWAY, ENGLEWOOD CO 80122
Jeffrey Busch director 7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814
Yvonne Fors director 1201 MONSTER RD SW STE 350, RENTON WA 98057
Michael I Ruxin director, officer: Chief Executive Officer HAEMONETICS CORPORATION INCORPORATED, 400 WOOD ROAD, BRAINTREE MA 02184
Avant Diagnostics, Inc 10 percent owner 1050 30TH STREET NW, SUITE 107, WASHINGTON DC 20007
Brian Gill Barnett officer: Chief Executive Officer 230 N SPRINGER, LOS ALTOS CA 94024
Robert Neal Holcomb director PO BOX 535, ROLLING FORK MS 39159
Volnie Carlos Fernando Alaman 10 percent owner, officer: Chief Operating Officer-Vitel MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000
Odabachian Manuel Cosme director, 10 percent owner, officer: Global Operations GM-Vitel MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000
Daniel S. Hoverman director C/O ONCBIOMUNE PHARMACEUTICALS INC.,, 11441 INDUSTRIPLEX BLVD, SUITE 190, BATON ROUGE LA 70809
Rice Charles L Jr director C/O ENTERGY CORPORATION LEGAL DEPT., 639 LOYOLA AVE., 26TH FLOOR, NEW ORLEANS LA 70113
Andrew Albert Kucharchuk director, officer: CFO & President 549 MILGATE PLACE, BATON ROUGE LA 70810
Jonathan Frederick Head director, officer: Chief Executive Officer 6144 HAGERSTOWN DRIVE, BATON ROUGE LA 70817